



**World Health  
Organization**

# **WHO COVID-19 vaccines research**

## **Advancing the development of pan-sarbecovirus vaccines**

25 March 2022

13:00 – 18:30 Central European Time CET

## **DRAFT Agenda**



**R&D Blueprint**

Powering research  
to prevent epidemics

In continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint is organizing a consultation to identify vaccine research priorities to facilitate further contributions of vaccines to achieve improved control of the pandemic everywhere.

During this forthcoming consultation global experts will review the available evidence, enumerate knowledge gaps, and outline research priorities related to pan-sarbecovirus vaccines. The objectives of the meeting are to:

- Review scientific advances and development approaches to enable the development of a pan-sarbecovirus vaccine
- Outline novel approaches for evaluation of pan-sarbecovirus vaccines, including in the context of the different variants of concern
- Discuss how we can prospectively evaluate vaccines intended to protect against viruses that are not yet circulating

**Chairperson: Stanley Plotkin**

Time	Topic	Speakers
13:00 – 13:10	Welcome address and WHO proposal regarding pan-sarbecovirus vaccines	WHO
13:10 – 13:20	Objectives of the meeting	Stanley Plotkin
<b>Session 1. State of the art for pan-sarbecovirus vaccines</b>		
13:20 – 13:30	Major challenges with the development of pan-coronavirus vaccines	Ralph Baric (University of North Carolina, US)
13:30 – 13:40	Clinical Epidemiology of SARS-1, MERS, Respiratory Coronavirus	Waleed Abdurhman AlJabr (King Fahad Medical City, Saudi Arabia)
13:40 – 13:50	Evolution of SARS-2	Marion Koopmans (Erasmus University, NL)
13:50 – 14:00	Geographic and Host distribution of Coronaviruses	William Karesh (Ecohealth Alliance)
14:00 – 14:10	Clinical characteristics of Coronaviruses infections	Stanley Perlman (university of Iowa Health Care, US)
14:10 – 15:20	Different strategies for vaccine development (10 min each)	Linfa Wang (Duke-NUS, Singapore) Kevin Saunders (Duke University, US) Kayvon Modjarrad (Walter Reed Army Institute of Research, US) David Veessler (University of Washington, US) Lu Lu (Fudan University, China) TBC Pamela Bjorkman (California Institute of Technology, US) Yves Levy (Inserm, France)
15:20 – 15:40	Framework for vaccine evaluation	Philip Krause
15:40 – 16:20	<u>Vaccine Developer's Panel</u> <ul style="list-style-type: none"> <li>What are the challenges you are experiencing with your candidate vaccine?</li> <li>What can the international research community do to facilitate the development of pan-sarbecovirus vaccines?</li> </ul>	Moderated by Marie-Paule Kieny  Rajeev Dhere, Serum Institute of India Hanneke Schuitemaker, Janssen Alexandre Le Vert, Osivax
16:20 – 16:30	Variant-proof v pan-sarbecovirus vaccines	Florian Krammer, Mount Sinai
16:30 – 17:10	<u>Panel discussion</u> How can we prospectively evaluate vaccines intended to protect against viruses that are not yet circulating?	Panel Discussion moderated by Phillip Krause Miles Davenport Kevin Saunders (Duke University, US) Eric Karikari-Boateng, (Foods and Drugs Authority, Ghana) Helen Rees (University of Witwatersrand, South Africa) Raymond Tellier (McGill University Health Centre, Canada) Malik Peiris (University of Hong Kong) Gustavo Mendes Lima Santos, (ANVISA, Brasil)
17:10 – 17:40	Ongoing initiatives to support Sarbecovirus vaccines development (2-3 minutes each)	Christina Cassetti (NIAID, US) Yves Levy (Inserm, France) Chris da Costa (CEPI)

17:40 – 18:00	A forum for discussion of Sarbecovirus vaccines development challenges: what are the key issues to discuss next	WHO
18:00 – 18:15	Overall conclusions and way forward	Philip Krause/AM/Plotkin
18:15 – 18:30	Next steps	WHO
18:30	<b>END OF MEETING</b>	